InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 992,100 shares, a drop of 12.2% from the April 30th total of 1,130,000 shares. Currently, 1.8% of the company's stock are short sold. Based on an average daily trading volume, of 319,200 shares, the days-to-cover ratio is presently 3.1 days.

Hedge Funds Weigh In On InflaRx

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC acquired a new position in shares of InflaRx in the fourth quarter valued at about $28,000. Cubist Systematic Strategies LLC grew its position in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. XTX Topco Ltd acquired a new stake in InflaRx during the first quarter worth approximately $38,000. Walleye Capital LLC acquired a new stake in InflaRx during the fourth quarter worth approximately $51,000. Finally, Geode Capital Management LLC grew its position in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after buying an additional 11,900 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IFRX. Guggenheim lifted their price objective on shares of InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, March 26th. Cantor Fitzgerald assumed coverage on shares of InflaRx in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st. Raymond James downgraded InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price on the stock. in a research report on Thursday, May 29th. Finally, Oppenheimer lowered their target price on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $6.60.

InflaRx Price Performance

NASDAQ IFRX remained flat at $0.85 during trading on Thursday. The company's stock had a trading volume of 321,929 shares, compared to its average volume of 276,298. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82. The firm has a market capitalization of $57.06 million, a PE ratio of -0.79 and a beta of 1.57. The firm's fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.80.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. On average, analysts forecast that InflaRx will post -1.04 earnings per share for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.